Well, T-Met-A is an antibody drug conjugate against C-Met. So the results from last year and even before that at ASCO, the monotherapy data, I think, established C-Met as a valid target in this disease. Now, I think it’s important to note that C-Met is expressed in virtually all of colorectal cancer. There’s different degrees of expression, but some degree of C-Met expression is expressed universally in colorectal cancer tumor cells...
Well, T-Met-A is an antibody drug conjugate against C-Met. So the results from last year and even before that at ASCO, the monotherapy data, I think, established C-Met as a valid target in this disease. Now, I think it’s important to note that C-Met is expressed in virtually all of colorectal cancer. There’s different degrees of expression, but some degree of C-Met expression is expressed universally in colorectal cancer tumor cells. So these agents are potentially going to play a role in virtually all patients with colorectal cancer. So the data I presented today was unselected for C-Met expression. So patients weren’t preselected for high levels of C-Met expression. And in that unselected patient population, we revealed the improvements in overall survival, although that was not statistically significant, probably due to the sample size, as well as the progression-free survival, which did have a hazard ratio that did not cross one confidence interval. So I think when you look at the monotherapy data, the combination data, we see that these antibody drug conjugates and C-Met have high activity beyond what we see with the standard of care and put C-Met on the map as a relevant target.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.